Day 27 — Medications That Help You Stop Drinking: The Brace
Yesterday ended with a map on the table — three generations, no blame — and one small instruction folded into the corner: save a question for a doctor. Today is that question. Because behind the reception desk there is, in effect, a drawer that stays shut far too often, and inside it are medicines that press on the exact circuits you've spent 26 days learning. One caps the endorphin glow so the first-drink spark stops firing. One rests a steadying hand on the seesaw while it heals. One bottles the protective flush you met yesterday. Two more quiet the noise of the loud weeks. Today: how each one works, what the numbers honestly say, who each tends to help — and how to ask for one without feeling like you're cheating.
Monday, 8:47 A.M.The doctor's office opened at 8:30. You know this because the number has been sitting in your phone since Thursday. You've opened the contact twice, thumb hovering over the green button, and twice found an urgent reason to check the weather instead.
It isn't the hold music. It's the sentence. I think I'm drinking too much. You've rehearsed it a dozen ways and none of them will come out of your mouth. Too dramatic. Not dramatic enough. Maybe you'll just mention the sleep thing.
Lock the phone. Pocket. Another day.
Here is the fact that should change the rehearsal. There are five medicines with real trial evidence for drinking — two of them named as first choices in the major treatment guidelines — and fewer than one person in ten who could benefit ever leaves an appointment with a prescription. Not because the medicines fail. Because patients don't ask and doctors don't offer. The sentence sticks on both sides of the desk, and the drawer stays shut while people white-knuckle something there is actual medicine for.
Today you get the contents of the drawer. And by tonight, the script that opens it.
The objectionThe brace
Before the drawer, deal with the voice — the one that pipes up somewhere between the parking lot and reception: medication is cheating. Real change is willpower. You should be able to do this yourself.
Day 9 taught you the move. Don't argue with a thought; check it. So check this one against a knee.
A person tears a ligament. They rehab it with a brace strapped around the joint. The brace does not do a single squat. It does not grow one fibre of muscle back. What it does is hold the joint steady so the work can happen — so that every rep builds strength instead of re-tearing the damage. And nobody at the gym walks over to the person in the brace and says: that's cheating.
That's the whole model for today. Not one of these five medicines lays a metre of new wiring. The groove in the grass from Day 3, the index card from Day 9, the spotlight reps from Day 15, the watering can from Day 16, the empty-hour list from Day 18 — that work stays yours. What the medicines do is hold the chemistry steady enough that your reps count: a glow that doesn't fire, a seesaw that doesn't slam, a consequence signed in the morning, a night that finally lets you sleep. A brace, while the muscle rebuilds.
And run the check one layer deeper while you're at it. I should be able to do this myself. You have now read 26 days on what alcohol did to a seesaw, a highlighter, a smoke alarm, a manager. "Myself" was never the whole story — chemistry has been at the table since the first pour. Using chemistry to leave the table isn't cheating. It's symmetry.
The capNaltrexone: the cap on the pen
Day 1 handed you the highlighter — dopamine marking this mattered, do it again. Part of how alcohol presses that highlighter is a burst of endorphins, the brain's homemade opioids, released when you drink. They land on their receptors, the reward circuit lights, the dopamine pop follows, and the evening gets marked. Day 14 showed you the sharpest edge of that pop: priming — the first drink that orders the second.
Naltrexone sits in the endorphin receptors like a cap on the pen. You can physically drink on it — nothing dramatic happens; that's a different medicine — the drink just lands flat. The glow doesn't arrive. The spark that orders the second drink fizzles instead of catching. The page stops being re-marked. And Day 11 told you what happens to marks that stop being refreshed: they fade.
The evidence starts in 1992, with two trials landing at once. In a Veterans Affairs study, about half as many people on naltrexone slid back into heavy drinking compared with placebo; an independent trial the same year, pairing it with coping-skills work, found the same signal. Pooling everything since, a 2014 analysis puts it plainly: for roughly every twelve people who take it, one more avoids returning to heavy drinking who otherwise wouldn't have. A real tilt of the odds — not magic. More on that arithmetic below.
It comes as a daily tablet or a monthly injection — the shot built for the honest fact that the day you most want to skip the pill is the day the old wiring is winning. And some clinicians prescribe it targeted: one tablet about an hour before an occasion where drinking is likely. The logic there is pure Day 3 in reverse — every drink taken without the glow actively unlearns the link. A cousin medicine, nalmefene, is approved in parts of Europe for exactly this as-needed use. Hold that thought for the ledger: this is the one medicine built for both roads.
Costs: a queasy first week or two for some (food helps), and it blocks opioid painkillers — a genuine safety item that gets its own line in the safety note.
The science behind this
Joseph Volpicelli and Stephanie O'Malley put naltrexone on the map with two independent trials in 1992 — in Volpicelli's Veterans Affairs study, roughly half as many drinkers on the medicine returned to heavy drinking. David Sinclair developed the targeted, take-it-before-the-occasion use of the same drug.
Acamprosate: the hand on the seesaw
Back to Day 2. Years of nightly weight on the calming side taught your brain to brick up the excitatory side — the glutamate side — just to stay level. Take the bottle away and the propped side slams skyward: the loudness, the wired-but-tired weeks, Day 12's volume knob at full turn. The bricks do come down, but on the repair crews' clocks from Day 5, not yours.
Acamprosate is a hand resting on the glutamate side while that slow demolition runs. Researchers still argue about the fine print of its grip, but the working picture is steady: it calms overexcited signalling so that quiet doesn't have to be earned hour by hour. It isn't sedating. It isn't euphoric. It isn't anything you can feel — and people quit taking it for exactly that reason, which is like firing the physio because the knee doesn't hurt during the exercises. The feeling of nothing is the product.
The evidence is strongest for people who have already stopped and want to stay stopped — that's where the large European trials showed their effect, and the pooled numbers land in the same place: roughly one extra person in twelve holds their abstinence who otherwise wouldn't. The timing follows from the job description: it usually starts after the last drink — and after any medically supervised stop — then runs for months while the bricks come down.
Practical notes: the kidneys clear it, not the liver, which often makes it the pick when the liver has taken damage. It's a few small tablets spread across the day — a nuisance, or, reframed, a built-in anchor habit. A loose stomach early on is the common complaint.
The boltDisulfiram: the flush in a bottle
Different logic entirely. The first two work on wanting and steadiness. This one leaves wanting completely alone and changes the consequences.
Start with the cleanup line: the body clears alcohol in two steps, and the step-two enzyme converts the toxic middle product — acetaldehyde — into something harmless. Disulfiram blocks step two. Drink on it and acetaldehyde pools within minutes: flushing, a pounding heart, nausea. Reliably. Every time.
You met this mechanism yesterday. Day 26's speed bump — the variant carried by hundreds of millions of people that slows step two natively and stands as one of the strongest protections against alcohol problems ever found. Disulfiram borrows that gene by prescription. The flush, in a bottle.
The trials are blunt about how it works and how it doesn't. Handed over to take alone, the results are weak — that was the finding of a large Veterans Affairs study. Taken each morning with a witness — a partner, a pharmacist, a clinic nurse — it holds. Which tells you what this medicine actually is: not a craving drug, a decision drug. Day 10's pre-commitment in chemical form. The manager signs the contract at 8 a.m., while strong, and the 6 p.m. wave breaks against a choice already made. It's patient, too — the block lingers for days after a missed tablet, so there's no same-day loophole to negotiate with yourself.
It is abstinence-only by definition, and strict about it: alcohol hides in sauces, mouthwash, some tonics (safety note again). And it is never, ever given to someone secretly. But for a certain reader — the one who does fine until the third Thursday, who would rather the door were locked than guarded — this is less a brace than a bolt, and some people love it for exactly that.
The science behind this
Richard Fuller's Veterans Affairs cooperative study is where the supervised-dose lesson comes from: handed over to take alone, disulfiram's results are weak; taken each morning with a witness, it holds.
Topiramate and gabapentin: the borrowed tools
Two more, borrowed from epilepsy and nerve-pain medicine, both used off-label for alcohol — meaning prescribed on trial evidence without a formal licence for this specific use. That's common and legal; knowing the word now means it won't rattle you at the pharmacy counter.
Topiramate leans on the same glutamate chatter that acamprosate steadies, and boosts calming traffic besides. Its unusual talent: it works in people who are still drinking. In the trials, people started it mid-stream, and heavy-drinking days drifted down over the following weeks. It's ramped up slowly, and the cost for some is real: word-finding stumbles, tingling fingertips, a mental fog — and Day 10 matters here, because the manager is barely back at his desk, and sanding down the desk isn't free. Plenty of people feel nothing; if you're one who fogs, that trade gets weighed honestly with the prescriber.
Gabapentin's speciality is the loud weeks. It calms the same overexcited signalling from another angle, and its trial results read like Days 7 and 12 in reverse: better sleep, less edge, more people holding on — that was a 2014 trial — with a twist from a 2020 study: the benefit concentrates in people whose withdrawal ran rough. The harder the seesaw slammed, the more this one helps. The 3 a.m. bill and the volume knob, one prescription aimed at both. The main cost is sleepiness, and because some people misuse it, prescribers keep an eye on it — a reasonable fence, not an accusation.
Neither is a first pick. Both are real tools when the first picks don't fit — a brain that can't afford fog but can't sleep either, a liver conversation, a starting line that isn't at zero yet.
The science behind this
Bankole Johnson's trials established topiramate in people who were still drinking, and Barbara Mason's 2014 trial established gabapentin for sleep and early abstinence. Raymond Anton's 2020 trial added the twist: the benefit concentrates in people whose withdrawal ran rough.
What the numbers honestly say
Yesterday's page made a promise, so here it is, plain.
Line up twelve people who have stopped and want to stay stopped, and give them all acamprosate for the next months: on average, one more of them stays off entirely than would have without it. Line up twelve on naltrexone: one more avoids sliding back into heavy drinking. That is what the research's "number needed to treat — about twelve" means, and the honesty cuts both ways. It means no pill on this page will carry most people by itself. It also means these are strong results by the standards of everyday medicine — some of the most widely taken preventive heart pills post longer odds than that, and nobody calls them a character flaw.
Second: the pills were tested alongside support, not instead of it. The largest American trial — COMBINE — found naltrexone earned its keep when paired with structured medical check-ins. Medicine plus reps beats either alone. The brace, worn to physio.
Third, the part that should make you slightly angry: these are cheap generics with decades of evidence, named first-line in the guidelines — and fewer than one person in ten with a drinking problem is ever offered one. By many counts, far fewer. The reasons are old training, stigma on both sides of the desk, and the cheating myth wearing a white coat. Knowing the numbers is how you outvote all three. The ask is tonight's exercise.
And the next shelf, briefly, because it's coming: there is work under way on medicines from other aisles — baclofen, already used in some countries when the liver is fragile, and the GLP-1 diabetes-and-weight drugs, where the first randomized trial of semaglutide, in 2025, reported fewer drinks on drinking days. Early and small, with larger trials running. Watch that space; don't wait for it.
The science behind this
Daniel Jonas's 2014 meta-analysis, commissioned by the U.S. government, supplies the one-in-twelve arithmetic for both first-line medicines, and Raymond Anton led COMBINE (2006), the largest American test of these medicines paired with structured support. Lorenzo Leggio at the National Institutes of Health leads the next generation, from baclofen for fragile livers to the 2025 semaglutide trial. As always, every figure here is a group average.
Two readers, one page
If you're stopping
Choosing among five medicines is prescriber work — it turns on your liver, your kidneys, your other prescriptions, your history. What belongs to you is the road you're on and the honest picture you bring. Naltrexone and acamprosate are the first-line pair. The rough edge between them: naltrexone shows its strength against the slide back into heavy drinking; acamprosate shows its strength in holding a quiet abstinence already begun. Prescribers often pick by organ — a tired liver points to acamprosate, kidney trouble points away from it — and by which failure mode worries you more.
If what you want is a lock rather than a brace, disulfiram with a morning witness is a legitimate, old-fashioned, effective choice. If the loud weeks are what keep breaking you — the 3 a.m. wakings, the edge — and especially if your withdrawal ran rough, gabapentin is the conversation to raise. A typical run is six to twelve months while the new wiring sets; coming off is a planned conversation, not a cliff, and going back on later is allowed. Braces come off, and go back on, as the joint needs.
If you're cutting back
This page does not skip you — one of these was practically built for your road. Naltrexone, daily or targeted an hour before an occasion, caps exactly the spark that orders the second drink; topiramate has real trial evidence for shrinking heavy days without requiring zero first. Acamprosate and disulfiram are not your tools.
And one hard sentence, held out with Day 21's open hand: a medicine can make fewer possible; it cannot answer whether fewer is sustainable for you. That's tomorrow — the fork, and its three honest questions. Bring yesterday's map and today's page with you when you go.
Both columns stay on the page, whichever you choose. Dimmed is not deleted.
A note on safety
First, the warning that leads every page of this series: if you've been drinking heavily every day, stopping suddenly can be physically dangerous. Shaking, sweating, a racing heart, confusion or seizures after stopping are medical symptoms — get medical help rather than pushing through.
Today's page is one more reason that standing rule exists: acamprosate typically starts after the last drink, and gabapentin sometimes appears inside a medically supervised stop — a clinician's call, made in a clinician's setting, never a home experiment.
Today's specifics. Everything on this page is prescription-only, and honesty is part of the dosage: the prescriber needs the true amount, the liver and kidney picture, pregnancy or plans for it, and every other pill and powder you take — including opioid painkillers and codeine cold syrups. And no pharmacy that skips the prescriber; websites selling these without a prescription are selling you the pill without the safety half, which was the only hard part.
Naltrexone and opioids don't mix, in either direction. Starting it with opioids in your system can trigger sudden withdrawal; while you're on it, opioid painkillers won't work in an emergency unless the doctors know. Carry a card or add it to your phone's medical ID, and tell every doctor and dentist you see.
Disulfiram means no alcohol in any form — cooking wine (it doesn't all burn off), mouthwash, some tonics and desserts — and the reaction can be dangerous, not just miserable. The block lingers up to two weeks after the last tablet. And it is never given to anyone without their knowledge. Ever.
Foggy, slowed, or overly sleepy on topiramate or gabapentin? Tell the prescriber and don't drive fuzzy; the ramp-up is adjustable, and suffering in silence isn't a virtue. And a slip while on these isn't a reason to quit them in silence — naltrexone keeps working through drinking events, disulfiram is the exception above, and Day 14's rule stands: report the stumble, keep the protocol running.
The script
You've written scripts before — Day 13's were for a room full of people. This one is four sentences, for one listener, and it may do more than any other page this month. Paper or notes app, ten minutes. First, the number, true: I've been drinking about ___ drinks, ___ nights a week, for around ___. No rounding down — the choice of medicine, and the dose, get built from that line. And whatever your number is, it will not be the biggest one your doctor hears this week; boring them is the goal. Second, the road: I'm working on stopping — or cutting down — and it's been harder than I expected. "Harder than I expected" is not a confession; it's the clinical signal that moves the conversation from advice to treatment. Third, the map: if yesterday's chart showed loading, add the four words that change the conversation's weight instantly — it runs in my family. Fourth, the ask: I've read that naltrexone and acamprosate are first-line treatments for this. Could we talk about whether one of them fits me? Naming them does two jobs — it shows you've done the reading, and it politely signals that you'll notice a shrug. Then read it aloud once, because the words are for your mouth to practise, not just your eyes, and clip it to the index card. The optional fifth step, only if you're ready: book the appointment tonight. Online booking exists precisely for sentences that stick on phones. Two minutes, and then it's real. You are not asking for a favour. You are asking for standard care that most people are never offered.
Tonight's plan is set.
Saved on this device only. Nothing here ever leaves your phone.
The drawer, and what's in it
| The medicine | What it is | Who it tends to help | What you do with it |
|---|---|---|---|
| Naltrexone (daily pill or monthly shot) | Caps the endorphin glow — the first drink stops ordering the second, and the evening fades off the highlights page | Either road: the one medicine built for stopping or cutting down | Ask about it as a first-line option; carry a card — it blocks opioid painkillers |
| Acamprosate | A steadying hand on the seesaw while the bricks come down; feels like nothing, and the nothing is the product | People already stopped who want to stay stopped — kidney-cleared, so often the pick for a tired liver | Started after the last drink, then kept up for months while the demolition runs |
| Disulfiram | Yesterday's protective flush by prescription — drink on it and be sick, every time | The reader aiming at zero who would rather the door were locked than guarded | The lock, not the brace: strongest when the morning dose has a witness |
| Topiramate | Turns down the glutamate noise; heavy days drift down even before quitting | People still drinking, whose starting line isn't at zero yet | Off-label, ramped slowly; weigh the fog and word-finding cost honestly |
| Gabapentin | Quiets the loud weeks — sleep and edge — from the same overexcited signalling, another angle | Most of all, people whose withdrawal ran rough | Off-label and sedating; used openly, monitored sensibly |
| The ask | Four sentences: the true number, the road, the family line, the request by name | Everyone — fewer than one person in ten is ever offered any of this | Read it aloud tonight, clip it to the index card, and book the slot |
Take these with you
Tap the bookmark to add a line to your collection — one pocket card, built across thirty days.
There are five medicines with real evidence for drinking — two of them first choices in the major guidelines — and fewer than one person in ten who could benefit is ever offered one.
Naltrexone caps the endorphin glow, so the first drink stops ordering the second and the evening stops getting highlighted — the one medicine built for both roads, stopping and cutting down.
Acamprosate rests a steadying hand on the Day 2 seesaw while the bricks come down; it feels like nothing, and the nothing is the product — it helps stopped people stay stopped.
Disulfiram is yesterday's protective flush in a bottle: it never touches wanting, it changes consequences — Day 10's pre-commitment in chemical form, strongest when the morning dose has a witness.
Topiramate shrinks heavy days even before quitting, and gabapentin quiets the loud weeks of sleep and edge — borrowed, off-label, and real when the first-line picks don't fit.
None of them lays a metre of new wiring. They hold the chemistry steady so your reps count — a brace on a healing knee, and the knee still does the physio.
A medicine for drinking is a brace, not a shortcut: it holds things steady while you rebuild, the rebuilding stays yours, and asking your doctor about one is not a confession or a favour — it's four sentences requesting standard care that works and is almost never offered. You've spent 26 days learning these circuits. You're allowed to use the tools that press on them.
Where this comes from, if you want to go deeper: Joseph Volpicelli's 1992 Veterans Affairs trial and Stephanie O'Malley's independent trial the same year put naltrexone on the map — in Volpicelli's study, roughly half as many drinkers on the medicine returned to heavy drinking. Raymond Anton led COMBINE (2006), the largest American test of these medicines paired with structured support, and the 2020 trial showing gabapentin helps most in people whose withdrawal ran rough. Daniel Jonas's 2014 meta-analysis, commissioned by the U.S. government, supplies the one-in-twelve arithmetic for both first-line medicines. Barbara Mason's 2014 trial established gabapentin for sleep and early abstinence; Bankole Johnson's trials did the same for topiramate in people still drinking. David Sinclair developed the targeted, take-it-before-the-occasion use of naltrexone, and the supervised-dose lesson for disulfiram traces to Richard Fuller's VA cooperative study. Lorenzo Leggio at the National Institutes of Health leads the next generation, from baclofen for fragile livers to the 2025 semaglutide trial. As always: every figure here is a group average, none of this is an internet purchase, and each medicine is a conversation with a prescriber who knows your whole picture — the family map included.